Search research articles
Contact Us
Filters
Showing results (41-50 of 77) with videos related to
Page
of 8
Sort By:
Blood Advances
|
December 19, 2023
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)
Tycel J Phillips, Abraham Avigdor, Ronit Gurion, et al.
Blood Advances
|
September 18, 2024
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma
Joseph E Maakaron, Adam Asch, Leslie Popplewell, et al.
Blood Cancer Discovery
|
April 17, 2026
A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Justin M Darrah, Indumathy Varadarajan, Amitkumar Mehta, et al.
JNCI Cancer Spectrum
|
December 16, 2022
Expanding access to early phase trials: the CATCH-UP.2020 experience
Joaquina C Baranda, Francisco J Diaz, Larry Rubinstein, et al.
Leukemia & Lymphoma
|
July 26, 2023
Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen
Sydney Dunn-Valadez, Srilakshmi Bathini, Kathleen E Purdy, et al.
Blood Advances
|
February 5, 2025
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study
Jason Westin, Tycel J Phillips, Amitkumar Mehta, et al.
Urologic Oncology
|
December 17, 2013
Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy
Gregory R Pond, Giuseppe Di Lorenzo, Andrea Necchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2023
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study
Michael Wang, Tanya Siddiqi, Leo I Gordon, et al.
Blood Advances
|
August 15, 2023
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
Adam J Olszewski, Tycel J Phillips, Marc S Hoffmann, et al.
Eclinicalmedicine
|
August 21, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study
Pier Luigi Zinzani, Marek Trněný, Vincent Ribrag, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 77) with videos related to
Sort By:
Page
of 8
Blood Advances
|
December 19, 2023
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)
Tycel J Phillips, Abraham Avigdor, Ronit Gurion, et al.
Blood Advances
|
September 18, 2024
Magrolimab plus rituximab with or without chemotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma
Joseph E Maakaron, Adam Asch, Leslie Popplewell, et al.
Blood Cancer Discovery
|
April 17, 2026
A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Justin M Darrah, Indumathy Varadarajan, Amitkumar Mehta, et al.
JNCI Cancer Spectrum
|
December 16, 2022
Expanding access to early phase trials: the CATCH-UP.2020 experience
Joaquina C Baranda, Francisco J Diaz, Larry Rubinstein, et al.
Leukemia & Lymphoma
|
July 26, 2023
Utility of end of induction bone marrow biopsy and survival outcomes in acute promyelocytic leukemia treated with fixed-dose induction regimen
Sydney Dunn-Valadez, Srilakshmi Bathini, Kathleen E Purdy, et al.
Blood Advances
|
February 5, 2025
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study
Jason Westin, Tycel J Phillips, Amitkumar Mehta, et al.
Urologic Oncology
|
December 17, 2013
Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy
Gregory R Pond, Giuseppe Di Lorenzo, Andrea Necchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 10, 2023
Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Mantle Cell Lymphoma Cohort From TRANSCEND NHL 001, a Phase I Multicenter Seamless Design Study
Michael Wang, Tanya Siddiqi, Leo I Gordon, et al.
Blood Advances
|
August 15, 2023
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
Adam J Olszewski, Tycel J Phillips, Marc S Hoffmann, et al.
Eclinicalmedicine
|
August 21, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study
Pier Luigi Zinzani, Marek Trněný, Vincent Ribrag, et al.
Page
of 8